Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in Medtronic PLC $MDT

Universal Beteiligungs und Servicegesellschaft mbH lowered its position in Medtronic PLC (NYSE:MDT) by 3.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,569,975 shares of the medical technology company’s stock after selling 51,468 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Medtronic were worth $149,524,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of MDT. Vanguard Group Inc. increased its stake in Medtronic by 1.5% during the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC lifted its stake in Medtronic by 1.1% in the second quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock valued at $2,448,699,000 after buying an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Medtronic by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock worth $1,854,616,000 after buying an additional 595,549 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after acquiring an additional 98,220 shares during the period. Finally, Invesco Ltd. grew its holdings in Medtronic by 3.9% during the second quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after acquiring an additional 666,557 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent analyst reports. Royal Bank Of Canada boosted their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Stifel Nicolaus boosted their price objective on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Wells Fargo & Company raised their price objective on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Price Performance

Shares of NYSE MDT opened at $98.64 on Wednesday. The stock has a fifty day simple moving average of $99.14 and a two-hundred day simple moving average of $95.06. The firm has a market cap of $126.46 billion, a price-to-earnings ratio of 26.59, a price-to-earnings-growth ratio of 2.55 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the business earned $1.26 earnings per share. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).